Acadia gets FDA nod for Nuplazid in capsule, tablet strengths
Acadia Pharmaceuticals has received the Food and Drug Administration’s approval of a new capsule dose formulation and a new tablet strength of Nuplazid, or pimavanserin, to help patients living with hallucinations and delusions associated with Parkinson’s disease psychosis.
A 34-mg dosage strength capsule formulation will provide patients with the recommended 34-mg once daily dose in a single, small capsule versus the current administration of two 17-mg tablets.
The FDA also gave its blessing for Acadia’s 10-mg tablet that provides an optimized lower dosage strength in those patients who are concomitantly receiving strong cytochrome 3A4 inhibitors, which can inhibit the metabolism of Nuplazid.
The Nuplazid 34-mg capsules and 10-mg tablets will be available by mid-August.
“We are very pleased with the FDA approval of the Nuplazid 34-mg capsule and 10-mg tablet, underscoring Acadia’s continued dedication to advancing safe and effective treatment options for patients living with hallucinations and delusions associated with Parkinson’s disease psychosis,” Acadia president and CEO, Steve Davis, said.
A 34-mg dosage strength capsule formulation will provide patients with the recommended 34-mg once daily dose in a single, small capsule versus the current administration of two 17-mg tablets.
The FDA also gave its blessing for Acadia’s 10-mg tablet that provides an optimized lower dosage strength in those patients who are concomitantly receiving strong cytochrome 3A4 inhibitors, which can inhibit the metabolism of Nuplazid.
The Nuplazid 34-mg capsules and 10-mg tablets will be available by mid-August.
“We are very pleased with the FDA approval of the Nuplazid 34-mg capsule and 10-mg tablet, underscoring Acadia’s continued dedication to advancing safe and effective treatment options for patients living with hallucinations and delusions associated with Parkinson’s disease psychosis,” Acadia president and CEO, Steve Davis, said.